Cargando…
Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells
BACKGROUND: Breast cancer is one the highest causes of female cancer death worldwide. Many standard chemotherapeutic agents currently used to treat breast cancer are relatively non-specific and act on all rapidly dividing cells. In recent years, more specific targeted therapies have been introduced....
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915983/ https://www.ncbi.nlm.nih.gov/pubmed/20650001 http://dx.doi.org/10.1186/1471-2407-10-390 |